Aurora Daljit Singh 内部人交易：近期 SEC Form 4 交易
过去 18 个月，Aurora Daljit Singh（CIK 1793971）在 1 家公司共报告 29 笔 SEC Form 4 内部人交易（最近一笔 2026-08-21）。
| 日期 | 公司 | 身份 | 类型 | 股数 | 市值 |
|---|---|---|---|---|---|
| 2026-08-21 | Neumora Therapeutics, Inc. (NMRA) | Title: Chief Operating and Development Officer | 买入 | 67,741 | $48,774 |
| 2026-08-21 | Neumora Therapeutics, Inc. (NMRA) | Title: Chief Operating and Development Officer | 卖出 | 67,741 | $102,587 |
| 2026-08-21 | Neumora Therapeutics, Inc. (NMRA) | Title: Chief Operating and Development Officer | 买入 | 21,685 | $15,613 |
| 2026-08-21 | Neumora Therapeutics, Inc. (NMRA) | Title: Chief Operating and Development Officer | 买入 | 45,026 | $32,419 |
| 2026-08-21 | Neumora Therapeutics, Inc. (NMRA) | Title: Chief Operating and Development Officer | 卖出 | 66,711 | $101,000 |
| 2026-08-21 | Neumora Therapeutics, Inc. (NMRA) | Title: Chief Operating and Development Officer | 买入 | 20,553 | $14,798 |
| 2026-08-21 | Neumora Therapeutics, Inc. (NMRA) | Title: Chief Operating and Development Officer | 卖出 | 20,553 | $32,780 |
| 2026-08-21 | Neumora Therapeutics, Inc. (NMRA) | Title: Chief Operating and Development Officer | 买入 | 21,055 | $15,160 |
| 2026-08-21 | Neumora Therapeutics, Inc. (NMRA) | Title: Chief Operating and Development Officer | 卖出 | 21,055 | $33,600 |
| 2026-08-19 | Neumora Therapeutics, Inc. (NMRA) | Title: Chief Operating and Development Officer | 买入 | 1 | $1 |
| 2026-08-19 | Neumora Therapeutics, Inc. (NMRA) | Title: Chief Operating and Development Officer | 买入 | 15,355 | $11,056 |
| 2026-08-19 | Neumora Therapeutics, Inc. (NMRA) | Title: Chief Operating and Development Officer | 买入 | 1,424 | $1,025 |
| 2026-08-19 | Neumora Therapeutics, Inc. (NMRA) | Title: Chief Operating and Development Officer | 买入 | 40,890 | $29,441 |
| 2026-08-19 | Neumora Therapeutics, Inc. (NMRA) | Title: Chief Operating and Development Officer | 卖出 | 57,670 | $86,822 |
| 2026-08-19 | Neumora Therapeutics, Inc. (NMRA) | Title: Chief Operating and Development Officer | 卖出 | 34,020 | $50,530 |
| 2026-08-19 | Neumora Therapeutics, Inc. (NMRA) | Title: Chief Operating and Development Officer | 买入 | 25,279 | $18,201 |
| 2026-08-19 | Neumora Therapeutics, Inc. (NMRA) | Title: Chief Operating and Development Officer | 买入 | 29,737 | $21,411 |
| 2026-08-19 | Neumora Therapeutics, Inc. (NMRA) | Title: Chief Operating and Development Officer | 卖出 | 55,016 | $82,783 |
| 2026-08-19 | Neumora Therapeutics, Inc. (NMRA) | Title: Chief Operating and Development Officer | 买入 | 34,162 | $24,597 |
| 2026-08-19 | Neumora Therapeutics, Inc. (NMRA) | Title: Chief Operating and Development Officer | 卖出 | 34,162 | $54,137 |
| 2026-08-19 | Neumora Therapeutics, Inc. (NMRA) | Title: Chief Operating and Development Officer | 买入 | 34,987 | $25,191 |
| 2026-08-19 | Neumora Therapeutics, Inc. (NMRA) | Title: Chief Operating and Development Officer | 卖出 | 34,987 | $55,486 |
| 2026-08-19 | Neumora Therapeutics, Inc. (NMRA) | Title: Chief Operating and Development Officer | 买入 | 13,268 | $9,553 |
| 2026-08-19 | Neumora Therapeutics, Inc. (NMRA) | Title: Chief Operating and Development Officer | 买入 | 17,732 | $12,767 |
| 2026-08-19 | Neumora Therapeutics, Inc. (NMRA) | Title: Chief Operating and Development Officer | 卖出 | 31,000 | $51,029 |
来源：SEC Form 4 申报文件 · 截至 2026-08-21